Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol

Reatul Karim, Sukrut Somani, Majed Al Robaian, Margaret Mullin, Rumelo Amor, Gail McConnell, Christine Dufès

Research output: Contribution to journalArticle

9 Citations (Scopus)

Abstract

The therapeutic potential of tocotrienol, a member of the vitamin E family of compounds with potent in vitro anti-cancer properties, is limited by its inability to specifically reach tumors following intravenous administration. The purpose of this study is to determine whether a novel tumor-targeted vesicular formulation of tocotrienol would suppress the growth of A431 epidermoid carcinoma and B16-F10 melanoma in vitro and in vivo.
In this work, we demonstrated that novel transferrin-bearing multilamellar vesicles entrapping α-T3 resulted in a dramatically improved (by at least 52-fold) therapeutic efficacy in vitro on A431 cell line, compared to the free drug. In addition, the intravenous administration of tocotrienol entrapped in transferrin-bearing vesicles resulted in tumor suppression for 30% of A431 and 60% of B16-F10 tumors, without visible toxicity. Mouse survival was enhanced by more than 13 days compared to controls administered with the drug solution only.
This tumor-targeted, tocotrienol-based nanomedicine therefore significantly improved the therapeutic response in cancer treatment.
LanguageEnglish
Pages79-87
Number of pages9
JournalJournal of Controlled Release
Volume246
Early online date18 Dec 2016
DOIs
Publication statusPublished - 28 Jan 2017

Fingerprint

Vitamin E
Intravenous Administration
Tocotrienols
Neoplasms
Transferrin
Nanomedicine
Experimental Melanomas
Therapeutics
alpha tocotrienol
Pharmaceutical Preparations
Squamous Cell Carcinoma
Cell Line
Growth
In Vitro Techniques

Keywords

  • tocotrienol
  • transferrin
  • cancer therapy
  • tumor targeting
  • delivery system
  • anti-cancer
  • vesicular formulation
  • epidermoid carcinoma

Cite this

Karim, Reatul ; Somani, Sukrut ; Al Robaian, Majed ; Mullin, Margaret ; Amor, Rumelo ; McConnell, Gail ; Dufès, Christine. / Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol. In: Journal of Controlled Release. 2017 ; Vol. 246. pp. 79-87.
@article{d68fd01727384aa3a0bbba7f0a4ec56e,
title = "Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol",
abstract = "The therapeutic potential of tocotrienol, a member of the vitamin E family of compounds with potent in vitro anti-cancer properties, is limited by its inability to specifically reach tumors following intravenous administration. The purpose of this study is to determine whether a novel tumor-targeted vesicular formulation of tocotrienol would suppress the growth of A431 epidermoid carcinoma and B16-F10 melanoma in vitro and in vivo. In this work, we demonstrated that novel transferrin-bearing multilamellar vesicles entrapping α-T3 resulted in a dramatically improved (by at least 52-fold) therapeutic efficacy in vitro on A431 cell line, compared to the free drug. In addition, the intravenous administration of tocotrienol entrapped in transferrin-bearing vesicles resulted in tumor suppression for 30{\%} of A431 and 60{\%} of B16-F10 tumors, without visible toxicity. Mouse survival was enhanced by more than 13 days compared to controls administered with the drug solution only. This tumor-targeted, tocotrienol-based nanomedicine therefore significantly improved the therapeutic response in cancer treatment.",
keywords = "tocotrienol, transferrin, cancer therapy, tumor targeting, delivery system, anti-cancer, vesicular formulation, epidermoid carcinoma",
author = "Reatul Karim and Sukrut Somani and {Al Robaian}, Majed and Margaret Mullin and Rumelo Amor and Gail McConnell and Christine Duf{\`e}s",
year = "2017",
month = "1",
day = "28",
doi = "10.1016/j.jconrel.2016.12.014",
language = "English",
volume = "246",
pages = "79--87",
journal = "Journal of Controlled Release",
issn = "0168-3659",

}

Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol. / Karim, Reatul; Somani, Sukrut; Al Robaian, Majed; Mullin, Margaret; Amor, Rumelo; McConnell, Gail; Dufès, Christine.

In: Journal of Controlled Release, Vol. 246, 28.01.2017, p. 79-87.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Tumor regression after intravenous administration of targeted vesicles entrapping the vitamin E α-tocotrienol

AU - Karim, Reatul

AU - Somani, Sukrut

AU - Al Robaian, Majed

AU - Mullin, Margaret

AU - Amor, Rumelo

AU - McConnell, Gail

AU - Dufès, Christine

PY - 2017/1/28

Y1 - 2017/1/28

N2 - The therapeutic potential of tocotrienol, a member of the vitamin E family of compounds with potent in vitro anti-cancer properties, is limited by its inability to specifically reach tumors following intravenous administration. The purpose of this study is to determine whether a novel tumor-targeted vesicular formulation of tocotrienol would suppress the growth of A431 epidermoid carcinoma and B16-F10 melanoma in vitro and in vivo. In this work, we demonstrated that novel transferrin-bearing multilamellar vesicles entrapping α-T3 resulted in a dramatically improved (by at least 52-fold) therapeutic efficacy in vitro on A431 cell line, compared to the free drug. In addition, the intravenous administration of tocotrienol entrapped in transferrin-bearing vesicles resulted in tumor suppression for 30% of A431 and 60% of B16-F10 tumors, without visible toxicity. Mouse survival was enhanced by more than 13 days compared to controls administered with the drug solution only. This tumor-targeted, tocotrienol-based nanomedicine therefore significantly improved the therapeutic response in cancer treatment.

AB - The therapeutic potential of tocotrienol, a member of the vitamin E family of compounds with potent in vitro anti-cancer properties, is limited by its inability to specifically reach tumors following intravenous administration. The purpose of this study is to determine whether a novel tumor-targeted vesicular formulation of tocotrienol would suppress the growth of A431 epidermoid carcinoma and B16-F10 melanoma in vitro and in vivo. In this work, we demonstrated that novel transferrin-bearing multilamellar vesicles entrapping α-T3 resulted in a dramatically improved (by at least 52-fold) therapeutic efficacy in vitro on A431 cell line, compared to the free drug. In addition, the intravenous administration of tocotrienol entrapped in transferrin-bearing vesicles resulted in tumor suppression for 30% of A431 and 60% of B16-F10 tumors, without visible toxicity. Mouse survival was enhanced by more than 13 days compared to controls administered with the drug solution only. This tumor-targeted, tocotrienol-based nanomedicine therefore significantly improved the therapeutic response in cancer treatment.

KW - tocotrienol

KW - transferrin

KW - cancer therapy

KW - tumor targeting

KW - delivery system

KW - anti-cancer

KW - vesicular formulation

KW - epidermoid carcinoma

U2 - 10.1016/j.jconrel.2016.12.014

DO - 10.1016/j.jconrel.2016.12.014

M3 - Article

VL - 246

SP - 79

EP - 87

JO - Journal of Controlled Release

T2 - Journal of Controlled Release

JF - Journal of Controlled Release

SN - 0168-3659

ER -